135 related articles for article (PubMed ID: 29262596)
1. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.
Alzrigat M; Párraga AA; Majumder MM; Ma A; Jin J; Österborg A; Nahi H; Nilsson K; Heckman CA; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Nov; 8(61):103731-103743. PubMed ID: 29262596
[TBL] [Abstract][Full Text] [Related]
2. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
3. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Alzrigat M; Jernberg-Wiklund H; Licht JD
Epigenomes; 2018 Sep; 2(3):. PubMed ID: 30761216
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
5. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.
Hernández-Muñoz I; Taghavi P; Kuijl C; Neefjes J; van Lohuizen M
Mol Cell Biol; 2005 Dec; 25(24):11047-58. PubMed ID: 16314526
[TBL] [Abstract][Full Text] [Related]
6. Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex.
Qian T; Lee JY; Park JH; Kim HJ; Kong G
Oncogene; 2010 Oct; 29(43):5818-27. PubMed ID: 20697353
[TBL] [Abstract][Full Text] [Related]
7. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
8. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
9. Ring1B contains a ubiquitin-like docking module for interaction with Cbx proteins.
Bezsonova I; Walker JR; Bacik JP; Duan S; Dhe-Paganon S; Arrowsmith CH
Biochemistry; 2009 Nov; 48(44):10542-8. PubMed ID: 19791798
[TBL] [Abstract][Full Text] [Related]
10. The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Bolomsky A; Muller J; Stangelberger K; Lejeune M; Duray E; Breid H; Vrancken L; Pfeiffer C; Hübl W; Willheim M; Weetall M; Branstrom A; Zojer N; Caers J; Ludwig H
Br J Haematol; 2020 Sep; 190(6):877-890. PubMed ID: 32232850
[TBL] [Abstract][Full Text] [Related]
11. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
Tiffen J; Gallagher SJ; Hersey P
Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.
Raaphorst FM; van Kemenade FJ; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
Am J Pathol; 2000 Sep; 157(3):709-15. PubMed ID: 10980109
[TBL] [Abstract][Full Text] [Related]
13. Polycomb group proteins and their roles in regulating stem cell development.
Huang BY; Pan XY; Li ZX; Wang ZC; Yu YS; Dou ZH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Jun; 34(3):281-5. PubMed ID: 22776663
[TBL] [Abstract][Full Text] [Related]
14. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
Momparler RL; Côté S
Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
[TBL] [Abstract][Full Text] [Related]
15. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.
Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A
J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
Breuer RH; Snijders PJ; Smit EF; Sutedja TG; Sewalt RG; Otte AP; van Kemenade FJ; Postmus PE; Meijer CJ; Raaphorst FM
Neoplasia; 2004; 6(6):736-43. PubMed ID: 15720799
[TBL] [Abstract][Full Text] [Related]
17. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
20. High histone acetylation and decreased polycomb repressive complex 2 member levels regulate gene specific transcriptional changes during early embryonic stem cell differentiation induced by retinoic acid.
Lee ER; Murdoch FE; Fritsch MK
Stem Cells; 2007 Sep; 25(9):2191-9. PubMed ID: 17525233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
